This preclinical publication supports the scientific rationale for Telomir-Zn but does not change the near-term risk profile. Monitor for initiation of the Phase 1/2 TNBC trial and any subsequent data readouts. No immediate trading catalyst from this filing alone.
Price Chart
Executive Summary
Telomir Pharmaceuticals announced a peer-reviewed publication of preclinical data for Telomir-Zn in triple-negative breast cancer (TNBC) and prostate cancer models. The study demonstrates iron-dependent KDM inhibition, tumor suppressor gene reactivation, anti-tumor and anti-metastatic activity, and synergy with paclitaxel. The company has an active IND for a Phase 1/2 trial in TNBC.
Key Facts
- Publication in Journal of Oncology Research and Therapy, Volume 11, Issue 3, on August 10, 2026
- Telomir-Zn inhibits histone demethylases (KDMs) by depleting intracellular iron, confirmed by iron-rescue experiments
- In TNBC xenografts, Telomir-Zn reduced primary tumor size and significantly reduced metastatic dissemination in HCC1806 model
- Combination with paclitaxel showed synergistic tumor reduction in BT-549 xenografts
- Company has active IND for Phase 1/2 clinical trial in advanced or metastatic TNBC
- Selectivity window: Telomir-Zn killed cancer cells at low concentrations while leaving normal cells unharmed at >50-fold higher concentrations
Financial Impact
No financial data or guidance provided in this filing
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans
- Company is pre-revenue and will require additional financing to complete clinical development
- Competition from other TNBC therapies and epigenetic drugs
- Heterogeneous response observed in MDA-MB-231 xenografts suggests patient stratification challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036742 |
| Exhibit: ex99-1.htm | 0001493152-26-036742 |
| Document: 0001493152-26-036742-index-headers.html | 0001493152-26-036742 |
| Document: 0001493152-26-036742-index.html | 0001493152-26-036742 |
| Document: 0001493152-26-036742.txt | 0001493152-26-036742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.20 | awaiting T+20 | — | $1.05 (−12.66%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $1.05 (−6.42%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $1.05 (−6.42%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $1.05 (−10.42%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $1.05 (−10.42%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $1.05 (−10.42%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $1.05 (−18.75%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $1.05 (−13.38%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $1.05 (−25.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers